Simcere expects 1H revenue up 27%-29% to RMB 4.55-4.61 billion

• Simcere guided 1H 2026 revenue at RMB 4.55-4.61 billion, up 26.9%-28.6% from RMB 3.59 billion a year earlier.
• Profit attributable to equity shareholders seen at RMB 810-860 million, up 34.8%-43.1% from restated RMB 601 million.
• Adjusted profit attributable to equity shareholders forecast at RMB 950 million to RMB 1 billion, up 46.5%-54.2% from restated RMB 649 million.
• Growth tied to higher innovative pharma revenue, stronger out-licensing income.
• Prior-period figures restated following the October 2025 acquisition of Xianwei (Hainan) Biotechnology, treated as common-control combination.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Simcere Pharmaceutical Group Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260730-12262592), on July 30, 2026, and is solely responsible for the information contained therein.